FDA Approves Acalabrutinib with Venetoclax for CLL or SLL By Ogkologos - March 4, 2026 170 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR Daughter Donates Hair to Mother After She Was Diagnosed with Stage... March 3, 2021 First Study to Demonstrate that PD1 Immune Checkpoint Blockade May Yield... December 4, 2023 New Task Force Focuses on Quality of Life for AYAs with... August 4, 2021 Pazopanib Shows Promise for Children, Adults with Soft Tissue Sarcomas September 9, 2020 Load more HOT NEWS SABCS 2021: New Research and Updates in Breast Cancer Treatment and... Similarity of Molecular Portraits in Synchronous Bilateral Breast Cancers Could be... Nivolumab Plus Ipilimumab Demonstrates Long-Term Survival Benefit in Patients with Advanced... FDA Approves Zanubrutinib for Waldenström’s Macroglobulinemia
